Evaluation and Management of Axillary Lymphadenopathy in Females

Initial Imaging Strategy

• For women ≥30 years old with axillary lymphadenopathy, diagnostic mammography (or digital breast tomosynthesis) is the mandatory first imaging study, followed immediately by axillary ultrasound at the same visit, as recommended by the American College of Radiology 1

Age-Stratified Imaging Protocol

• Women ≥30 years should begin with diagnostic mammography including standard mediolateral oblique and craniocaudal views, plus magnification views to identify microcalcifications indicating potential ductal carcinoma in situ, according to the American College of Radiology 1
• Women <30 years should use targeted breast ultrasound as the initial study to avoid unnecessary radiation exposure in this lower-risk population, as suggested by the American College of Radiology 1

Ultrasound Evaluation of the Axilla

• Axillary ultrasound is the primary modality for characterizing lymph node morphology and determining whether masses are solid or cystic, as stated by the Journal of the American College of Radiology 2, 3

Tissue Diagnosis Requirements

• Complete all imaging studies (mammography and ultrasound) before proceeding to tissue diagnosis, as biopsy-related changes confuse subsequent image interpretation, according to the American College of Radiology 1

Management Based on Initial Findings

• If malignancy is confirmed in axillary node but no breast primary identified, perform breast MRI to identify occult primary breast cancer, which is detected in more than two-thirds (approximately 70%) of patients with suspicious axillary lymphadenopathy and negative conventional imaging, as recommended by the Journal of the American College of Radiology 1, 2, 3
• For clinically node-negative breast cancer ≤2 cm, sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) as the standard of care, according to the Journal of the American College of Radiology 4

Surgical Management for Confirmed Breast Cancer

• SLNB alone is non-inferior to ALND for 10-year overall survival in patients with T1 or T2 invasive breast cancer and no palpable axillary adenopathy (Z0011 trial), as stated by the Journal of the American College of Radiology 4
• For patients with 1-2 positive sentinel nodes, SLNB alone is non-inferior to complete ALND, according to the Journal of the American College of Radiology 4, 3

Bilateral Axillary Lymphadenopathy

• Bilateral presentation more commonly suggests systemic processes including infections, inflammatory conditions, or hematologic malignancies rather than breast cancer, as suggested by the American College of Radiology 5

Advanced Imaging Considerations

• CT chest with IV contrast should be reserved for patients with elevated liver function tests, pulmonary or abdominal symptoms, or abnormal physical examination findings, according to the Journal of the American College of Radiology 2

Critical Clinical Pitfalls to Avoid

• Never rely on physical examination alone for assessment, as both sensitivity and specificity are limited, as stated by the American College of Radiology 3
• Do not delay biopsy of suspicious nodes, as early diagnosis significantly impacts treatment planning and prognosis, according to the American College of Radiology 3
• Do not assume benign etiology even when reactive changes are common—bilateral presentation warrants tissue diagnosis to exclude lymphoma, as suggested by the American College of Radiology 3, 5

Management of Solitary Small Axillary Lymph Nodes in Adults

Initial Clinical Assessment

• Perform a comprehensive clinical evaluation to look for additional sites of adenopathy (e.g., cervical, supraclavicular, inguinal) and for non‑breast causes such as recent infections, skin lesions, or systemic symptoms. 6, 7
• Conduct a bilateral clinical breast examination to detect any palpable masses, asymmetry, nipple discharge, or skin changes. 6

Indications for Diagnostic Imaging

• If the axillary node persists beyond 2–4 weeks, increases in size, becomes fixed or hard, or if overall clinical suspicion is heightened, proceed promptly to age‑appropriate imaging. 6, 7

Imaging Protocol (Women ≥ 30 years)

• Order diagnostic mammography (or digital breast tomosynthesis) together with targeted axillary ultrasound during the same visit; this approach is endorsed by the NCCN and ACR guidelines. 6, 7
• Complete all imaging studies before any tissue biopsy to avoid imaging artefacts caused by biopsy‑related changes. 6, 7

Management Based on Imaging Findings

Negative or Benign Imaging

• When imaging is negative or shows benign features, continue clinical observation; schedule a follow‑up examination in 4–6 weeks if the node appears reactive. 6, 7

Suspicious Imaging Features

• If ultrasound reveals suspicious morphology (e.g., cortical thickening > 3 mm, loss of fatty hilum, irregular borders), perform an ultrasound‑guided core‑needle biopsy (preferred over fine‑needle aspiration). 6, 7

Expected Etiology of a Small, Recent Node

• A pea‑sized node (≈ 5–8 mm) present for only one week in an otherwise healthy adult is most likely reactive adenopathy secondary to a minor infection, inflammation, or local skin irritation. 6

Clinical Features Supporting Observation

• Short duration (≈ 1 week) – malignant nodes typically persist and enlarge over weeks to months.
• Small size – nodes larger than 1 cm carry higher concern for malignancy.
• Solitary presentation – isolated axillary adenopathy is uncommon without a palpable breast mass. All three points favor observation. 6

Avoiding Unnecessary Testing

• Do not initiate imaging for every small, mobile lymph node of short duration; most reactive nodes resolve spontaneously within 2–4 weeks. 6

Red‑Flag Findings Requiring Immediate Imaging

• Hard, fixed, or matted lymph nodes.
• Node size exceeding 1–2 cm.
• Associated breast mass, skin changes, or nipple discharge.
• Constitutional symptoms (fever, night sweats, weight loss).
• Personal history of breast cancer or high‑risk breast lesions.
  *Presence of any of these findings warrants immediate diagnostic mammography and ultrasound without a waiting period. 6